X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to advance company’s clinical trial for pediatric brain cancer, evaluating 186RNL (rhenium-186 obisbemeda) that emits beta energy with a short half-life and sufficient energy for destroying tumor tissue.
Lead Product(s): Rhenium-186 Obisbemeda
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: United States Department of Defense
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 22, 2024
Details:
186RNL (Rhenium (186Re) obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors. It is being evaluated for the treatment of leptomeningeal metastases.
Lead Product(s): Rhenium (186 Re) Obisbemeda
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
186RNL (rhenium-186 obisbemeda) is a injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in CNS tumors, which is investigated for the treatment of Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases.
Lead Product(s): Rhenium-186 Obisbemeda
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2023
Details:
186RNL (rhenium-186 obisbemeda) is a injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in CNS tumors, which is investigated for the treatment of leptomeningeal metastases.
Lead Product(s): Rhenium-186 Obisbemeda
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
The funding will cover the majority of the development costs of the Company’s lead investigational targeted radiotherapeutic, 186RNL (rhenium-186 obisbemeda), for the treatment of patients with leptomeningeal metastases (LM).
Lead Product(s): Rhenium-186 Obisbemeda
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: CPRIT
Deal Size: $17.6 million Upfront Cash: Undisclosed
Deal Type: Funding September 11, 2023
Details:
186RNL (rhenium-186 obisbemeda) is a injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in CNS tumors. It has the potential to reduce risks and improve outcomes for CNS cancer patients, with a more targeted and potent radiation dose.
Lead Product(s): Rhenium-186 Obisbemeda
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
Under the agreement, Piramal will produce additional cGMP liposome intermediate drug product to meet the increase in demand for its lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, for ongoing and planned clinical trials.
Lead Product(s): Rhenium Obisbemeda
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Piramal Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration May 02, 2023
Details:
186RNL (rhenium-186 obisbemeda) is a injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in CNS tumors. It has the potential to reduce risks and improve outcomes for CNS cancer patients, with a more targeted and potent radiation dose.
Lead Product(s): Rhenium-186 Obisbemeda
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
Details:
186RNL (rhenium-186 obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation for destroying cancerous tissue in CNS tumors in a safe, effective and convenient manner to optimize patient outcomes.
Lead Product(s): Rhenium-186 Obisbemeda
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
186RNL (rhenium-186 obisbemeda) is a injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in CNS tumors. It has the potential to reduce risks and improve outcomes for CNS cancer patients, with a more targeted and potent radiation dose.
Lead Product(s): Rhenium-186 Nanoliposome
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
